FIELD: medicine, pharmaceutics.
SUBSTANCE: what is offered is using 40-O-(2-hydroxyethyl)-rapamycin for preparing a pharmaceutical composition for treating a pancreatic tumour. It is shown that 40-O-(2-hydroxyethyl)-rapamycin has reduced the pancreatic tumour growth, and has shown antiangiogenic activity. The manifested antitumour responses have been produced by intermittent administration of the compound every two days a week or twice a week.
EFFECT: reduction of the tumour growth rate.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| BIOMARKERS | 2005 |
|
RU2429297C2 |
| BIOMARKER | 2005 |
|
RU2385944C2 |
| STENTS WITH COATING CONTAINING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYL-AMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINAMIN | 2003 |
|
RU2341266C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
